Sales & Marketing

Deal includes potential additional payments of up to $140 million.

Partnership aims to enhance therapeutic benefit and safety.

The FDA's OPDP has sternly cautioned AstraZeneca for misleading claims in the promotional materials of its Breztri Aerosphere inhalation aerosol.

The company anticipates that the offering will help maximize life sciences brands’ commercial potential.

Bridget Seay of epocrates delves into drug launches in a digital-forward market, exploring how pharmaceutical companies can navigate complex patient journeys, strike a balance between traditional and digital marketing tactics, and ethically engage with healthcare professionals and empowered patients amidst ever-changing regulations.

Treatment indicated for BRCA-positive metastatic castration resistant prostate cancer.

H1 Mobile to offer latest information and research in multiple fields.

Deal to focus on Xpovio, a multiple myeloma treatment, in mainland China.

Purchase aims to develop therapies for people living with metabolic diseases.

Continued approval to be based on verification and description of clinical benefit in confirmatory trials.

Joint venture to combine artificial intelligence with biosciences’ dataset to identify novel therapy targets.

Collaboration intends to inspire creativity in healthcare and pharma industries.

New indication focuses on metastatic rearranged during transfection fusion-positive non-small cell lung cancer.

Partnership aims to identify small molecule candidates’ activity towards tumor suppressor protein.

Treatment indicated for patients aged 12 months and older.

The precision of programmatic advertising is reshaping the way life sciences brands engage with healthcare professionals, offering enhanced personalization, scale, and optimization in today's digital landscape.

Clinical trials report Izervay slowed disease progression as early as six months.

Extension complements pharmaceutical’s total lab solutions portfolio.

Decision comes amid recommendation from agency’s Committee for Medicinal Products for Human Use.

Treatment indicated for adult patients with metastatic colorectal cancer.

Deal comes amid companies’ bankruptcy filings.

Addition expected to provide approximately $1 billion in capital.

Agreement includes request to dismiss pending lawsuit.

Treatment is the first of its kind to focus on endometrial cancer.

Industry veteran Charles Pirraglia demystifies the journey of bringing life-changing therapies to the Canadian market, from understanding drug pricing to navigating direct-to-consumer advertising rules.

Syfovre linked to multiple cases of retinal vasculitis.

New deal to focus on commercialization efforts in Latin America.

Total deal expected to be worth approximately $7.3 billion.

Partnership intended to enhance development plan of biopharma’s drug candidate.

Research discovered no new safety signals.